Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Oral IL-23 Blocker Shows Durable Psoriasis Control at 1 Year

Summary by dermatologytimes.com
The trial presented at EADV 2025 confirmed that icotrokinra’s efficacy is consistent with injectable IL-23 inhibitors while offering an oral option.

2 Articles

Weatherford DemocratWeatherford Democrat
Lean Left

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies

Read Full Article
dermatologytimes.comdermatologytimes.com

Oral IL-23 Blocker Shows Durable Psoriasis Control at 1 Year

The trial presented at EADV 2025 confirmed that icotrokinra’s efficacy is consistent with injectable IL-23 inhibitors while offering an oral option.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Weatherford Democrat broke the news in on Wednesday, September 17, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Weatherford icon

Weatherford

News
For You
SearchBlindspotLocal